Table 3.

Adverse events associated with Atezo/Beva (n = 130).

Adverse Event	Any n (%)	Grade 3 ≥ n (%)
Total adverse events	126 (96.9%)	47 (36.1%)
Liver injury	57 (43.8%)	8 (6.1%)
Hypertension	54 (41.5%)	9 (6.9%)
Proteinuria	37 (28.5%)	12 (9.2%)
Fatigue	36 (27.6%)	1 (0.7%)
Skin disorder	32 (24.6%)	1 (0.7%)
Fever	30 (23.0%)	2 (1.5%)
Hoarseness	21 (16%)	0 (0.0%)
Decreased appetite	20 (15.3%)	0 (0.0%)
Hypothyroidism	18 (13.8%)	0 (0.0%)
Diarrhea	17 (13.0%)	1 (0.7%)
Bleeding	17 (13.0%)	9 (6.9%)
Hypopituitarism	3 (2.3%)	3 (2.3%)
Heart failure	3 (2.3%)	3 (2.3%)
Drug-induced pneumonia	2 (1.5%)	2 (1.5%)
Infusion reaction	5 (3.8%)	0 (0.0%)

Abbreviations: Atezo/Beva, atezolizumab plus bevacizumab.